Results 41 to 50 of about 5,256,367 (214)

The Myth of the Placebo Response

Frontiers in Psychiatry, 2019
The placebo response is a myth. It does not exist in reality, and continuing to name it is hindering the optimal application of science to healing in medicine.
Wayne B. Jonas
doaj   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Ultra-overt therapy: a novel medical approach centered on patient consciousness

Frontiers in Integrative Neuroscience
Within the realms of human and artificial intelligence, the concepts of consciousness and comprehension are fundamental distinctions. In the clinical sphere, patient awareness regarding medication and its physiological processes plays a crucial role in ...
Kamran Shirbache, Amirreza Liaghat, Sanam Saeifar, Ahmadreza Nezameslami, Ali Shirbacheh, Hamid Nasri, Hamidreza Namazi   +6 more
doaj   +1 more source

Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. [PDF]

PLoS ONE, 2018
Recent studies show that placebo response has grown significantly over time in clinical trials for antidepressants, ADHD medications, antiepileptics, and antidiabetics.
Arif Khan, Kaysee Fahl Mar, Joshua Schilling, Walter A Brown   +3 more
doaj   +1 more source

Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF312

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intracerebral hemorrhage (ICH) causes high morbidity and mortality, with neurotoxic inflammation driven by infiltrating monocytes. This study is an in‐depth longitudinal examination of the immune response during the first week of ICH in the presence and absence of the immunomodulatory drug BAF312 (Siponimod).
Jonathan Howard DeLong, Sebastian Díaz‐Pérez, Kevin Navin Sheth, Jang‐Ho Cha, C. J. Malanga, Patricia G. M. Wagner, Nicole Pezous, Aurelie Hanin, Kyle B. Walsh, H. E. Hinson, Lauren Hachmann Sansing   +10 more
wiley   +1 more source

Possible Strategies to Mitigate Placebo or Vehicle Response in Dry Eye Disease Trials: A Narrative Review

Ophthalmology and Therapy, 2023
Many candidate drugs for dry eye disease (DED) have been assessed over the years in pursuit of demonstrating efficacy in both signs and symptoms. However, patients with DED have very limited treatment options for management of both signs and symptoms of ...
Michela Montecchi-Palmer, Min Wu, Maurizio Rolando, Charis Lau, Victor L. Perez Quinones, Reza Dana   +5 more
doaj   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Clinical response to placebo botulinum toxin injection in cervical dystonia—a systematic review and meta-analysis

Dystonia
BackgroundCervical dystonia is the most common form of focal dystonia and is the most studied neurological condition in patients receiving botulinum toxin.
Emma Wetmore, Henry Roberts, Alicia A. Livinski, Terance Camacho, Chyanne Eaton, Gina Norato, Mark Hallett, Mark Stacy   +7 more
doaj   +1 more source

An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials

Clinical and Translational Science, 2022
Randomized, placebo‐controlled trials for binge eating disorder (BED) have revealed highly variable, and often marked, rates of short‐term placebo response.
Rahul K. Goyal, Shamir N. Kalaria, Susan L. McElroy, Mathangi Gopalakrishnan   +3 more
doaj   +1 more source

Placebo and Nocebo: What are the reasons why each individual reacts differently [PDF]

, 2022
openL'obiettivo della tesi è quello di individuare, se esistono, le motivazioni ed i fattori che sono coinvolti nel verificarsi dell'effetto placebo e dell'effetto nocebo.
FORESTI, FEDERICA
core